Eli Lilly Q3 FY26: where the revenue came from and where it went
The whole income statement of Eli Lilly for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Jul 1 – Sep 30, 2026
- Reported
- Oct 29, 2026
Revenue$24.4B
+39% year over year
Gross profit$20.5B
84% margin
Operating profit$8.6B
35% margin
Net profit$6.5B
26% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 24.4 | 100% | +39% |
| Mounjaro | 10.7 | 44% | +65% |
| Zepbound | 5.4 | 22% | +49% |
| Other revenue | 2.0 | 8% | |
| Jardiance | 1.6 | 7% | +65% |
| Verzenio | 1.5 | 6% | +3% |
| Cardiometabolic health | 1.2 | 5% | +13% |
| Other oncology | 1.1 | 4% | +16% |
| Trulicity | 0.9 | 4% | −14% |
| Cost of revenue | −3.9 | 16% | |
| Gross profit | 20.5 | 84% margin | +1pp |
| SG&A | −3.1 | 13% | −3pp |
| Other | −8.7 | 36% | |
| Operating profit | 8.6 | 35% margin | −7pp |
| Interest & other costs | −0.2 | ||
| Tax | −2.0 | ||
| Net profit | 6.5 | 26% margin | −5pp |
5 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest